FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPI	ROVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MUELLER PETER			$ \underline{\mathbf{v}} $	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
			/A 4: -1 -11 - \	<u>M</u>	<u>IA</u> ['	VRTX]]				2		(give title	Other (s	-
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 07/12/2007						CSO&EVP Drug Innov&Realization				
130 WAVERLY STREET				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)											- 1	,	led by One Re	porting Perso	n
CAMBR	IDGE M	IA	02139									Form fi Person	led by More th	an One Repo	rting
(City)	(S	state)	(Zip)												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
Date			. Transaction ate Month/Day/Y	Execution Date,		Code (Instr. 5)			d (A) or r. 3, 4 and		es Formally (D) (Following (I) (I	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
Derivative Conversion Da		3. Transaction Date Execution I (Month/Day/Year) if any (Month/Day		Date, Transaction Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$28.84	07/12/2007		A		36,250		10/12/2007 ⁽¹⁾	07/11/2017	Common Stock	36,250	\$0	36,250	D	

Explanation of Responses:

1. Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/12/2007.

Remarks:

Valerie L. Andrews, Attorney-

07/16/2007

In-Fact
** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.